文章名稱引用次數(shù)

• Clinical advances in gene therapy updates on clinical trials of gene therapy in haemophilia22
• Immune tolerance induction in paediatric patients with haemophilia A and inhibitors receiving emicizumab prophylaxis22
• A multicentre, open-label study of emicizumab given every 2 or 4 weeks in children with severe haemophilia A without inhibitors21
• The changing face of immune tolerance induction in haemophilia A with the advent of emicizumab20
• Defining extended half-life rFVIIIA critical review of the evidence19
• Treatment of bleeding episodes in haemophilia A complicated by a factor VIII inhibitor in patients receiving Emicizumab. Interim guidance from UKHCDO Inhibitor Working Party and Executive Committee17
• Core outcome set for gene therapy in haemophilia: Results of the coreHEM multistakeholder project16
• Management of bleeding and invasive procedures in haemophilia A patients with inhibitor treated with emicizumab (Hemlibra (R)): Proposals from the French network on inherited bleeding disorders (MHEMO), the French Reference Centre on Haemophilia, in collaboration with the French Working Group on Perioperative Haemostasis (GIHP)15
• High proportion of patients with bleeding of unknown cause in persons with a mild-to-moderate bleeding tendency: Results from the Vienna Bleeding Biobank (VIBB)13
• Women with bleeding disorders13